Monica Girotra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7959159/publications.pdf

Version: 2024-02-01

		759233	
13	857	12	13
papers	citations	h-index	g-index
1.0	10	1.0	1207
13	13	13	1387
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology, 2017, 13, 195-207.	9.6	515
2	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectrum, 2018, 2, pky021.	2.9	92
3	IgA antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers. International Journal of Cancer, 2000, 87, 824-828.	5.1	37
4	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. British Journal of Anaesthesia, 2020, 124, 251-260.	3.4	35
5	Immune Checkpoint Inhibitor–Associated Diabetes: A Single-Institution Experience. Diabetes Care, 2020, 43, 3106-3109.	8.6	28
6	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6129-6143.	2.2	28
7	Cancer immunotherapy–related adverse events: causes and challenges. Supportive Care in Cancer, 2020, 28, 6111-6117.	2.2	22
8	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. Journal of Bone Oncology, 2017, 7, 32-37.	2.4	21
9	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6119-6128.	2.2	20
10	Extended Survival After Surgical Resection for Pituitary Metastases: Clinical Features, Management, and Outcomes of Metastatic Disease to the Sella. Oncologist, 2020, 25, e789-e797.	3.7	19
11	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Supportive Care in Cancer, 2020, 28, 6175-6181.	2.2	15
12	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer, 2020, 28, 6145-6157.	2,2	14
13	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6159-6173.	2.2	11